RESUMEN
The 5-hydroxytryptamine 2C receptor (5-HTR2C) is a class G protein-coupled receptor (GPCR) enriched in the hypothalamus and the brain stem, where it has been shown to regulate energy homeostasis, including feeding and glucose metabolism. Accordingly, 5-HTR2C has been the target of several anti-obesity drugs, though the associated side effects greatly curbed their clinical applications. Dissecting the specific neural circuits of 5-HTR2C-expressing neurons and the detailed molecular pathways of 5-HTR2C signaling in metabolic regulation will help to develop better therapeutic strategies towards metabolic disorders. In this review, we introduced the regulatory role of 5-HTR2C in feeding behavior and glucose metabolism, with particular focus on the molecular pathways, neural network, and its interaction with other metabolic hormones, such as leptin, ghrelin, insulin, and estrogens. Moreover, the latest progress in the clinical research on 5-HTR2C agonists was also discussed.
Asunto(s)
Encéfalo/fisiología , Metabolismo Energético/genética , Receptor de Serotonina 5-HT2C/fisiología , Animales , Encéfalo/metabolismo , Estrógenos/fisiología , Ghrelina/fisiología , Homeostasis/genética , Humanos , Hipotálamo/metabolismo , Hipotálamo/fisiología , Insulina/fisiología , Leptina/fisiología , Red Nerviosa/fisiología , Receptor de Serotonina 5-HT2C/metabolismo , Transducción de Señal/genéticaRESUMEN
An electrophysiological bioassay was used to isolate the active compound from Hochuekkito (HET), which the current authors previously described as having potent agonist action against serotonin 2C receptors (5-HT2CR). Synthetic 5-HT2CR mRNA was injected into Xenopus oocytes to specifically express these receptors. Crude extracts and purified products were subjected to an electrophysiological bioassay using the voltage clamp method. HET stimulated a 5-HT2CR-induced current response, whereas Juzentaohoto (JTT), which has anti-depressive action similar to that of HET, did not. Current responses were not observed with an extract mixed with five types of herbal medicines common to HET and JTT but were detected with an extract with the five types of herbal medicines found in HET alone (Hoc5). When the responses to each of the five types of Hoc5 were examined, current responses were noted with Cimicifugae rhizoma (CR) and Citrus unshiu Markovich extracts. Since efficacy and the EC50 value were higher for CR, its constituents were separated using three-dimensional high-performance liquid chromatography and the current response at each of the isolated peaks was examined. One constituent displayed a strong response and was identified as a single substance with a molecular weight of 283.1393 based on liquid chromatography/mass spectrometry. These results will contribute to the isolation of 5-HT2CR-stimulating constituents in HET and the identification of trace constituents with agonist action.
Asunto(s)
Medicamentos Herbarios Chinos/farmacología , Oocitos/efectos de los fármacos , Receptor de Serotonina 5-HT2C/fisiología , Agonistas del Receptor de Serotonina 5-HT2/farmacología , Animales , Bioensayo , Medicamentos Herbarios Chinos/química , Fenómenos Electrofisiológicos , Oocitos/fisiología , Fitoquímicos/análisis , Fitoquímicos/farmacología , ARN Mensajero/administración & dosificación , Receptor de Serotonina 5-HT2C/genética , Serotonina/farmacología , Agonistas del Receptor de Serotonina 5-HT2/análisis , Xenopus laevisRESUMEN
RATIONALE: Adding reward-concurrent cues to a rat gambling task (rGT) increases risky choice. This cued version of the task may reflect an "addiction-like" cognitive process, more similar to human gambling than the uncued task. Serotonergic drugs that target 5-HT2 receptors alter mechanisms linked to impulse control. However, relatively little is known regarding the impact of such agents on either risky decision making, or the ability of conditioned stimuli to bias the choice process, despite potential relevance to addiction development and treatment. OBJECTIVES: The aim of this study was to determine the effects of SB 242,084 and M100907, selective antagonists at the 5-HT2C and 5-HT2A receptors respectively, as well as the selective 5-HT2C receptor agonist Ro-60-0175, on performance of both cued and uncued versions of the rGT. RESULTS: SB 242,084 significantly and dose-dependently increased choice of the most optimal option in the cued rGT only, despite concurrently increasing impulsive responses made prematurely on both the cued and uncued rGT. M100907 and Ro-60-0175 did not alter risky decision making, but nevertheless produced the expected decrease in premature responses on both task variants. CONCLUSIONS: These findings demonstrate that the 5-HT2 receptor-mediated regulation of risky decision making and motor impulsivity can be pharmacologically dissociated and further show that the presence of highly salient reward-paired cues critically alters the neurochemical regulation of the choice process. Importantly, these results suggest that 5-HT2C receptor antagonists may be of use in disrupting maladaptive patterns of decision making.
Asunto(s)
Señales (Psicología) , Toma de Decisiones/efectos de los fármacos , Juego de Azar/psicología , Receptor de Serotonina 5-HT2C , Recompensa , Antagonistas del Receptor de Serotonina 5-HT2/farmacología , Estimulación Acústica/métodos , Animales , Condicionamiento Operante/efectos de los fármacos , Condicionamiento Operante/fisiología , Toma de Decisiones/fisiología , Relación Dosis-Respuesta a Droga , Etilaminas/farmacología , Indoles/farmacología , Masculino , Estimulación Luminosa/métodos , Ratas , Ratas Long-Evans , Receptor de Serotonina 5-HT2C/fisiologíaRESUMEN
In the turkey, exogenous serotonin (5-hydroxytryptamine, 5-HT) increases prolactin (PRL) secretion by acting through the dopaminergic (DAergic) system. In the present study, infusion of the 5-HT(2C) receptor agonist, (R)(-)-DOI hydrochloride (DOI), into the third ventricle stimulates PRL secretion, whereas the 5-HT(1A) receptor agonist, (+/-)-8-OH-DPAT hydrobromide (DPAT), inhibits PRL secretion. Using the immediate-early gene, c-fos, as an indicator of neuronal activity, in situ hybridization histochemistry showed preferential c-fos co-localization within tyrosine hydroxylase immunoreactive neurons (the rate limiting enzyme in DA synthesis) in the areas of the nucleus preopticus medialis (POM) and the nucleus premammillaris (PMM), in response to DPAT and DOI, respectively. To clarify the involvement of 5-HT(1A) and 5-HT(2C) receptors in PRL regulation, their mRNA expression was determined on hypothalamic tissue sections from birds in different reproductive stages. A significant difference in 5-HT1A receptor was observed, with the POM of hypoprolactinemic short day and photorefractory birds showing the highest expression. 5-HT2C receptors mRNA did not change during the reproductive cycle. The data presented support the notion that DA neurons in the PMM and POM mediate the stimulatory and inhibitory effects of 5-HT, respectively, on PRL secretion and the 5-HTergic system can both stimulate and inhibit PRL secretion.
Asunto(s)
Proteínas Aviares/fisiología , Hipotálamo/metabolismo , Prolactina/metabolismo , Receptor de Serotonina 5-HT1A/fisiología , Receptor de Serotonina 5-HT2C/fisiología , Pavos/metabolismo , Animales , Femenino , Expresión Génica , Fenómenos Fisiológicos ReproductivosRESUMEN
David Horrobin's membrane phospholipid theory of schizophrenia has held up well over time because his therapeutic prediction that dietary supplementation with eicosapentaenoic acid (EPA) would have a therapeutic effect has been partially verified and undergoes continued testing. In the final version of his theory, he hypothesized that there was hyperactivity of phosphoslipase A(2) (PLA(2)) or a related enzyme but did not explain how the hyperactivity came about. It is known that serotonergic 5HT(2A/2C) receptors are coupled to PLA(2), which hydrolyzes both arachidonic acid (AA) and EPA from diacylglycerides at the sn-2 position. In this paper, Horrobin's theory is combined with a previously published theory of chronic stress in which it was hypothesized that a disinhibited dorsal raphe nucleus, the principal nucleus of the serotonergic system, can organize the neuropathology of diseases such as migraine, hypertension, and the metabolic syndrome. The new or combined theory is that schizophrenia is a disease of chronic stress in which a disinhibited DRN causes widespread serotonergic overdrive in the cerebral cortex. This in turn causes overdrive of cPLA(2) and both central and peripheral depletion of AA and EPA. Because EPA is present in smaller amounts, it falls below threshold for maintaining an intracellular balance between AA-derived and EPA-derived second messenger cascades, which leads to abnormal patterns of neuronal firing. There are two causes of neuronal dysfunction: the disinhibited DRN and EPA depletion. Schizophrenia is statistically associated with metabolic syndrome, hypertension, and migraine because they form a cluster of diseases with similar pathophysiology. The theory provides an explanation for both the central and peripheral phospholipid abnormalities in schizophrenia. It also explains the role of stress in schizophrenia, elevated serum PLA(2) activity in schizophrenia, the relationship between untreated schizophrenia and metabolic syndrome, and the therapeutic rationale for EPA.
Asunto(s)
Encéfalo/enzimología , Citosol/enzimología , Lípidos de la Membrana/fisiología , Fosfolipasas A2/metabolismo , Fosfolípidos/fisiología , Receptor de Serotonina 5-HT2A/fisiología , Receptor de Serotonina 5-HT2C/fisiología , Esquizofrenia/fisiopatología , Estrés Psicológico/fisiopatología , Humanos , Espectroscopía de Resonancia Magnética , Modelos Teóricos , Esquizofrenia/enzimología , Estrés Psicológico/enzimologíaRESUMEN
Allosteric modulators of the serotonin (5-HT) 5-HT(2C) receptor (5-HT(2C)R) present a unique drug design strategy to augment the response to endogenous 5-HT in a site- and event-specific manner with great potential as novel central nervous system probes and therapeutics. To date, PNU-69176E is the only reported selective positive allosteric modulator for the 5-HT(2C)R. For the first time, an optimized synthetic route to readily access PNU-69176E (1) and its diastereomer 2 has been established in moderate to good overall yields over 10 steps starting from commercially available picolinic acid. This synthetic approach not only enables a feasible preparation of a sufficient amount of 1 for use as a reference compound for secondary pharmacological studies, but also provides an efficient synthesis of key intermediates to develop novel and simplified 5-HT(2C)R allosteric modulators. Compound 1 and its diastereomer 2 were functionally characterized in Chinese hamster ovary (CHO) cells stably transfected with the 5-HT(2C)R using an intracellular calcium (Ca(i) (2+)) release assay. Compound 1 demonstrated efficacy and potency as an allosteric modulator for the 5-HT(2C)R with no intrinsic agonist activity. Compound 1 did not alter 5-HT-evoked Ca(i) (2+) in CHO cells stably transfected with the highly homologous 5-HT(2A)R. In contrast, the diastereomer 2 did not alter 5-HT-evoked Ca(i) (2+) release in 5-HT(2A)R-CHO or 5-HT(2C)R-CHO cells or exhibit intrinsic agonist activity.
Asunto(s)
Galactósidos/síntesis química , Galactósidos/farmacología , Piperidinas/síntesis química , Piperidinas/farmacología , Receptor de Serotonina 5-HT2C/metabolismo , Regulación Alostérica/efectos de los fármacos , Regulación Alostérica/fisiología , Animales , Células CHO , Calcio/metabolismo , Cricetinae , Cricetulus , Evaluación Preclínica de Medicamentos/métodos , Galactósidos/química , Humanos , Piperidinas/química , Receptor de Serotonina 5-HT2C/fisiología , EstereoisomerismoRESUMEN
BACKGROUND: Genetic variation in the promoter region of HTR2C encoding for the 5-HT(2C) receptor is associated with antipsychotic-induced weight gain. Several studies have investigated the regulatory potential of associated variants using gene-reporter systems. Establishing associated polymorphisms as causal variants may aid in the identification of the molecular mechanisms of phenotypic variation. AIMS & METHODS: To this end we examined the binding of nuclear factors from rat hypothalamus to two polymorphisms in HTR2C, rs3813929 (-759C/T) and rs518147 (-697C/G) using electromobility shift assays. For rs518147, allele-specific RNA folding was also investigated. RESULTS: Both polymorphisms bound nuclear factors, identifying the sequence fragments as regulatory elements. Importantly, rs3813929 (-759C/T) altered DNA-protein interactions with the weight gain-resistant allele abolishing the formation of two complexes. The formation of allele-specific RNA loops was also observed for rs518147. CONCLUSION: These data establish rs3813929 (-759C/T) as a functional polymorphism and suggest disruption of DNA-protein interactions as a mechanism by which HTR2C expression is perturbed leading to an influence on antipsychotic-induced weight gain.
Asunto(s)
Antipsicóticos/efectos adversos , Polimorfismo de Nucleótido Simple/genética , Receptor de Serotonina 5-HT2C/genética , Aumento de Peso/efectos de los fármacos , Aumento de Peso/genética , Animales , Variación Genética/genética , Hipotálamo/efectos de los fármacos , Hipotálamo/fisiología , Unión Proteica/genética , Mapeo de Interacción de Proteínas/métodos , Ratas , Receptor de Serotonina 5-HT2C/fisiologíaRESUMEN
Cancer anorexia-cachexia syndrome is characterized by decreased food intake, weight loss, muscle tissue wasting and psychological distress, and this syndrome is a major source of increased morbidity and mortality in cancer patients. This study aimed to clarify the gut-brain peptides involved in the pathogenesis of the syndrome and determine effective treatment for cancer anorexia-cachexia. We show that both ghrelin insufficiency and resistance were observed in tumor-bearing rats. Corticotropin-releasing factor (CRF) decreased the plasma level of acyl ghrelin, and its receptor antagonist, α-helical CRF, increased food intake of these rats. The serotonin 2c receptor (5-HT2cR) antagonist SB242084 decreased hypothalamic CRF level and improved anorexia, gastrointestinal (GI) dysmotility and body weight loss. The ghrelin receptor antagonist (D-Lys3)-GHRP-6 worsened anorexia and hastened death in tumor-bearing rats. Ghrelin attenuated anorexia-cachexia in the short term, but failed to prolong survival, as did SB242084 administration. In addition, the herbal medicine rikkunshito improved anorexia, GI dysmotility, muscle wasting, and anxiety-related behavior and prolonged survival in animals and patients with cancer. The appetite-stimulating effect of rikkunshito was blocked by (D-Lys3)-GHRP-6. Active components of rikkunshito, hesperidin and atractylodin, potentiated ghrelin secretion and receptor signaling, respectively, and atractylodin prolonged survival in tumor-bearing rats. Our study demonstrates that the integrated mechanism underlying cancer anorexia-cachexia involves lowered ghrelin signaling due to excessive hypothalamic interactions of 5-HT with CRF through the 5-HT2cR. Potentiation of ghrelin receptor signaling may be an attractive treatment for anorexia, muscle wasting and prolong survival in patients with cancer anorexia-cachexia.
Asunto(s)
Anorexia/etiología , Caquexia/etiología , Carcinoma Hepatocelular/tratamiento farmacológico , Medicamentos Herbarios Chinos/farmacología , Ghrelina/antagonistas & inhibidores , Ghrelina/fisiología , Neoplasias Hepáticas/tratamiento farmacológico , Transducción de Señal/efectos de los fármacos , Animales , Anorexia/tratamiento farmacológico , Anorexia/mortalidad , Caquexia/tratamiento farmacológico , Caquexia/mortalidad , Carcinoma Hepatocelular/etiología , Carcinoma Hepatocelular/mortalidad , Hormona Liberadora de Corticotropina/farmacología , Hormona Liberadora de Corticotropina/fisiología , Modelos Animales de Enfermedad , Sinergismo Farmacológico , Medicamentos Herbarios Chinos/administración & dosificación , Ghrelina/deficiencia , Hipotálamo/efectos de los fármacos , Hipotálamo/metabolismo , Hipotálamo/fisiología , Neoplasias Hepáticas/metabolismo , Neoplasias Hepáticas/mortalidad , Masculino , Ratas , Ratas Wistar , Receptor de Serotonina 5-HT2C/fisiología , Receptores de Ghrelina/antagonistas & inhibidores , Receptores de Ghrelina/fisiología , Estudios Retrospectivos , Transducción de Señal/genética , Análisis de SupervivenciaRESUMEN
Mice lacking 5-HT 2C receptors (5-HT(2C)Rs) displayed hepatic insulin resistance, a phenotype normalized by re-expression of 5-HT(2C)Rs only in pro-opiomelanocortin (POMC) neurons. 5-HT(2C)R deficiency also abolished the anti-diabetic effects of meta-chlorophenylpiperazine (a 5-HT(2C)R agonist); these effects were restored when 5-HT(2C)Rs were re-expressed in POMC neurons. Our findings indicate that 5-HT(2C)Rs expressed by POMC neurons are physiologically relevant regulators of insulin sensitivity and glucose homeostasis in the liver.
Asunto(s)
Regulación de la Expresión Génica , Resistencia a la Insulina/fisiología , Hígado/metabolismo , Neuronas/metabolismo , Proopiomelanocortina/biosíntesis , Receptor de Serotonina 5-HT2C/biosíntesis , Animales , Tronco Encefálico/metabolismo , Glucosa/metabolismo , Homeostasis/fisiología , Hipotálamo/metabolismo , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Ratones Transgénicos , Neuronas/fisiología , Proopiomelanocortina/fisiología , Receptor de Serotonina 5-HT2C/genética , Receptor de Serotonina 5-HT2C/fisiologíaRESUMEN
A new and novel non-SSRI potential treatment option for major depressive disorders is Valdoxen (agomelatine) which is currently in phase III clinical studies. Valdoxen is a norepinephrine disinhibitor (NNDI) and is also an antagonist of the 5-HT(2C) receptor.
Asunto(s)
Acetamidas , Antidepresivos , Norepinefrina/agonistas , Antagonistas del Receptor de Serotonina 5-HT2 , Acetamidas/efectos adversos , Acetamidas/química , Acetamidas/farmacología , Acetamidas/uso terapéutico , Animales , Antidepresivos/efectos adversos , Antidepresivos/química , Antidepresivos/farmacología , Antidepresivos/uso terapéutico , Ensayos Clínicos Fase III como Asunto , Método Doble Ciego , Evaluación Preclínica de Medicamentos , Fatiga/inducido químicamente , Cefalea/inducido químicamente , Humanos , Náusea/inducido químicamente , Ensayos Clínicos Controlados Aleatorios como Asunto , Receptor de Melatonina MT1/agonistas , Receptor de Melatonina MT2/agonistas , Receptor de Serotonina 5-HT2C/efectos de los fármacos , Receptor de Serotonina 5-HT2C/fisiologíaRESUMEN
BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) are widely used to treat anxiety and depressive disorders. These agents may cause upper gastrointestinal (GI) symptoms that lead to their discontinuation. We examined whether SSRIs modify physiologic GI motor activities in freely moving rats. METHODS: The SSRIs fenfluramine, fluvoxamine, paroxetine, and fluoxetine were administered to 24-hour food-deprived rats, and then GI motility was measured in conscious, freely moving rats using a strain gauge force transducer method. Plasma acyl ghrelin levels were determined by enzyme immunoassay. RESULTS: Plasma acyl ghrelin levels were analyzed in conjunction with fasted motor activities. Acyl ghrelin was increased in association with the occurrence of Phase III-like contractions of the migrating motor complex in the antrum and duodenum. SSRIs decreased acyl ghrelin and changed Phase III-like contractions to fed-like motor activities. Both effects were blocked by 5-HT2c, but not 5-HT1b, receptor antagonist. Neither melanocortin 4 nor the 3/4 receptor antagonists blocked this motor effect, although they restored the anorexia induced by SSRIs. The improving effect on GI motility by 5-HT2c receptor (5-HT2cR) antagonist disappeared after treatment with a growth-hormone secretagogue receptor antagonist, whereas ghrelin or ghrelin-releasing drug such as TJ-43 changed SSRI-induced fed-like motor activities to fasted activities. CONCLUSIONS: SSRIs have inhibitory effects on acyl ghrelin and GI motor activities through 5-HT2cR. Our study identifies the importance and divergence of central 5-HT2cR pathways that regulate GI motor activities through ghrelin and feeding/energy metabolism via melanocortin 4 receptor signaling.
Asunto(s)
Motilidad Gastrointestinal/efectos de los fármacos , Ghrelina/fisiología , Receptor de Serotonina 5-HT2C/fisiología , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Agonistas del Receptor de Serotonina 5-HT2 , Animales , Medicamentos Herbarios Chinos/farmacología , Ingestión de Alimentos/efectos de los fármacos , Fenfluramina/farmacología , Fluoxetina/farmacología , Fluvoxamina/farmacología , Motilidad Gastrointestinal/fisiología , Ghrelina/sangre , Ghrelina/farmacología , Hormona del Crecimiento/sangre , Inyecciones Intraventriculares , Masculino , Oligopéptidos/farmacología , Paroxetina/farmacología , Piperazinas/farmacología , Ratas , Ratas Wistar , Receptores de Ghrelina/antagonistas & inhibidores , Antagonistas del Receptor de Serotonina 5-HT2 , Antagonistas de la Serotonina/farmacologíaRESUMEN
The limitations of current antidepressant medications merit the exploration of alternative agents with novel antidepressant mechanisms of action. The established clinical finding that desynchronization of internal rhythms plays an important role in the pathophysiology of depressive disorders has stimulated the idea that resetting normal circadian rhythms may have antidepressant potential. Recent experiments using the novel melatonin receptor agonist and serotonin 2 (5-HT2c) receptor antagonist agomelatine (S20098; N[2-(7-methoxy-1-naphthyl)ethyl]- acetamide) revealed a notable chronobiotic activity and clear antidepressant-like effects in a variety of preclinical models. Binding studies performed in vitro proved that agomelatine is a high-affinity agonist at both the melatonin MT1 and MT2 receptor types. In addition, these studies revealed that agomelatine, in contrast to melatonin, blocks 5-HT2c receptors with significant affinity. Antagonism of 5-HT2c receptors is reported for various established antidepressant compounds. The antidepressant properties of agomelatine are thus based on its melatonergic actions and 5-HT2c receptor antagonism.
Asunto(s)
Acetamidas/farmacología , Antidepresivos/farmacología , Relojes Biológicos/fisiología , Trastorno Depresivo Mayor/fisiopatología , Drogas en Investigación/farmacología , Animales , Relojes Biológicos/efectos de los fármacos , Encéfalo/efectos de los fármacos , Encéfalo/fisiopatología , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Humanos , Melatonina/sangre , Receptor de Melatonina MT1/agonistas , Receptor de Melatonina MT1/fisiología , Receptor de Melatonina MT2/agonistas , Receptor de Melatonina MT2/fisiología , Receptor de Serotonina 5-HT2C/fisiología , Antagonistas del Receptor de Serotonina 5-HT2 , TupaiidaeRESUMEN
Serotonin (5-HT), the endogenous nonselective 5-HT receptor agonist, activates the inositol 1,4,5-triphosphate/calcium (InsP3/Ca2+) signaling pathway and exerts both stimulatory and inhibitory actions on cAMP production and GnRH release in immortalized GnRH neurons. The high degree of similarity between the signaling and secretory responses elicited by GnRH and 5-HT prompted us to target specific 5-HT receptor subtypes to deconvolute the complex actions of these agonists on signal transduction and GnRH release. Specific mRNA transcripts for 5-HT1A, 5-HT2C, 5-HT4, and 5-HT7 were identified in immortalized GnRH neurons (GT1-7). The rate of firing of spontaneous action potentials (APs) by hypothalamic GnRH neurons and cAMP production and pulsatile GnRH release in GT17 cells were profoundly inhibited during activation of the Gi-coupled 5-HT1A receptor. Treatment with a selective agonist to activate the Gq-coupled 5-HT2C receptor increased the rate of firing of spontaneous APs, stimulated InsP3 production and caused a delayed increase in GnRH release. Selective activation of the Gs-coupled 5-HT4 receptor also increased the rate of firing of APs, stimulated cAMP production, and caused a sustained and robust increase in GnRH release. The ability of 5-HT receptor subtypes expressed in GnRH neurons to activate single or multiple G proteins in a time- and dose-dependent manner differentially regulates the phospholipase C/InsP3/Ca2+, and adenylyl cyclase/cAMP signaling pathways, and thereby regulates the frequency and amplitude of pulsatile GnRH release. This process, in conjunction with the modulation of spontaneous electrical activity of the GnRH neuron, contributes to the control of the pulsatile mode of neuropeptide secretion that is characteristic of GnRH neuronal function in vivo and in vitro.
Asunto(s)
Hormona Liberadora de Gonadotropina/metabolismo , Neuronas/fisiología , Neurosecreción/fisiología , Receptores de Serotonina/fisiología , Transducción de Señal/fisiología , Potenciales de Acción , Animales , Células Cultivadas , AMP Cíclico/metabolismo , Feto/citología , Subunidades alfa de la Proteína de Unión al GTP/metabolismo , Hipotálamo/citología , Hipotálamo/metabolismo , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Neurosecreción/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Receptor de Serotonina 5-HT1A/efectos de los fármacos , Receptor de Serotonina 5-HT1A/fisiología , Receptor de Serotonina 5-HT2C/efectos de los fármacos , Receptor de Serotonina 5-HT2C/fisiología , Receptores de Serotonina/efectos de los fármacos , Receptores de Serotonina 5-HT4/efectos de los fármacos , Receptores de Serotonina 5-HT4/fisiología , Serotonina/farmacología , Antagonistas de la Serotonina/farmacología , Agonistas de Receptores de Serotonina/farmacología , Transducción de Señal/efectos de los fármacos , Fosfolipasas de Tipo C/metabolismoRESUMEN
Isorhynchophylline is a major oxindole alkaloid found in Uncaria species which have long been used in traditional Chinese medicine. Here, we investigated the effects of isorhynchophylline and isorhynchophylline-related alkaloids on 5-hydroxytryptamine (5-HT) receptor-mediated behavioural responses in mice and 5-HT-evoked current responses in Xenopus oocytes expressing 5-HT2A or 5-HT2C receptors. Isorhynchophylline dose-dependently inhibited 5-HT2A receptor-mediated head-twitch but not 5-HT1A receptor-mediated head-weaving responses evoked by 5-methoxy-N,N-dimethyltryptamine. Pretreatment with reserpine, a monoamine-depleting agent, enhanced the head-twitching, but did not influence the effect of isorhynchophylline on the behavioural response. Isocorynoxeine, an isorhynchophylline-related alkaloid in which the configuration of the oxindole moiety is the same as in isorhynchophylline, also reduced the head-twitch response in reserpinized mice over the same dose range as isorhynchophylline, while both rhynchophylline and corynoxeine, stereoisomers of isorhynchophylline and isocorynoxeine, did not. None of the alkaloids tested had an effect on meta-chlorophenylpiperazine-induced hypolocomotion, a 5-HT2C receptor-mediated behavioural response. In experiments in vitro, isorhynchophylline and isocorynoxeine dose-dependently and competitively inhibited 5-HT-evoked currents in Xenopus oocytes expressing 5-HT2A receptors, but had less of a suppressive effect on those in oocytes expressing 5-HT2C receptors. These results indicate that isorhynchophylline and isocorynoxeine preferentially suppress 5-HT2A receptor function in the brain probably via a competitive antagonism at 5-HT2A receptor sites and that the configuration of the oxindole moiety of isorhynchophylline is essential for their antagonistic activity at the 5-HT2A receptor.
Asunto(s)
Alcaloides/farmacología , Encéfalo/efectos de los fármacos , Receptor de Serotonina 5-HT2A/fisiología , Aminopiridinas/farmacología , Animales , Conducta Animal/efectos de los fármacos , Encéfalo/fisiología , Relación Dosis-Respuesta a Droga , Femenino , Alcaloides Indólicos , Ketanserina/farmacología , Masculino , Potenciales de la Membrana/efectos de los fármacos , Metoxidimetiltriptaminas/farmacología , Mianserina/farmacología , Ratones , Ratones Endogámicos ICR , Actividad Motora/efectos de los fármacos , Oocitos/efectos de los fármacos , Oocitos/fisiología , Oxindoles , Técnicas de Placa-Clamp , Piperazinas/farmacología , Ratas , Receptor de Serotonina 5-HT2A/genética , Receptor de Serotonina 5-HT2C/genética , Receptor de Serotonina 5-HT2C/fisiología , Serotonina/farmacología , Antagonistas del Receptor de Serotonina 5-HT2 , Antagonistas de la Serotonina/farmacología , XenopusRESUMEN
The Siberian hamster provides a physiological model for understanding the hypothalamic control of energy metabolism as it undergoes annual photoperiod-regulated cycles of body weight (i.e. fattening in summer, and catabolism of fat stores in winter). As a first step to investigate whether enhanced serotonergic (5-HT) tone might underlie the catabolic processes in short days, we investigated whether serotonergic stimulation can produce catabolic actions in fat hamsters housed in long days. Acute treatment with the serotonin reuptake inhibitor (+/-) fenfluramine (8 mg/kg, i.p.) produced a prolonged, dose-dependent reduction in food intake in both photoperiods. Behavioural observations and radiotelemetry analyses revealed that this anorectic effect of fenfluramine was associated with short-term increases in locomotor activity and in core body temperature. In a subsequent series of studies, hamsters were pretreated with the 5-HT2C receptor antagonist SB242084 (4 mg/kg, i.p.). This 5-HT2C receptor antagonist completely blocked the anorectic actions of fenfluramine, but did not decrease the hyperthermia or hyperlocomotion induced by fenfluramine; thus, the anorectic actions of fenfluramine probably reflect actions via the 5-HT2C receptor. Consistent with these observations, treatment of hamsters with the 5-HT2C receptor agonist VER 3323 (10 mg/kg, i.p.) or the 5-HT1B/2C receptor agonist mCPP (3 mg/kg, i.p.) reduced food intake. The response to manipulation of serotonergic pathways was not affected by the ambient photoperiod in any of these studies. We conclude that the anorectic actions of fenfluramine are not an indirect consequence of serotonergic actions on arousal pathways, and that its actions on feeding in the Siberian hamster are most likely to be mediated by the 5-HT2C receptor.
Asunto(s)
Regulación del Apetito/fisiología , Ingestión de Alimentos/fisiología , Metabolismo Energético/fisiología , Hipotálamo/fisiología , Receptor de Serotonina 5-HT2C/fisiología , Aminopiridinas/farmacología , Análisis de Varianza , Animales , Regulación del Apetito/efectos de los fármacos , Composición Corporal , Cricetinae , Relación Dosis-Respuesta a Droga , Ingestión de Alimentos/efectos de los fármacos , Metabolismo Energético/efectos de los fármacos , Conducta Alimentaria/efectos de los fármacos , Conducta Alimentaria/fisiología , Femenino , Fenfluramina/farmacología , Hipotálamo/efectos de los fármacos , Indoles/farmacología , Phodopus , Fotoperiodo , Receptor de Serotonina 5-HT2C/efectos de los fármacos , Estaciones del Año , Inhibidores Selectivos de la Recaptación de Serotonina/farmacologíaRESUMEN
The effects of [+/-]-2,5-dimethoxy-4-iodoaminophentamine, a serotonin(2A/2C) receptor agonist, on pharyngeal airflow mechanics were examined in isoflurane-anesthetized lean and obese Zucker rats. The pharyngeal pressure associated with flow limitation, maximum inspiratory flow, oronasal resistance, genioglossus muscle activity, and arterial blood pressure (BP) were measured before and after the intravenous administration of the agonist. A robust activation of the genioglossus muscle in all lean and obese rats was associated with decreased upper airway (UA) collapsibility (p < 0.05), unchanged maximum flow, and increased oronasal resistance (p < 0.05) in both groups. The changes in UA mechanics and BP after the drug were similar in lean and obese rats. The serotonin agonist had no effect on UA mechanics in a group of paralyzed (pancuronium bromide) rats, despite similar elevations in BP. There was a smaller decrease (p < 0.05) in UA collapsibility that was also associated with increased upstream resistance when the drug was administered after bilateral hypoglossal nerve transection. We conclude that systemic administration of a serotonin(2A/2C) receptor agonist improves UA collapsibility predominantly, but not exclusively, via stimulation of the hypoglossal nerves and also increases upstream resistance, at least in part, through activation of nonhypoglossal motoneuronal pools innervating the UA muscles.
Asunto(s)
Anfetaminas/uso terapéutico , Modelos Animales de Enfermedad , Obesidad/complicaciones , Agonistas de Receptores de Serotonina/uso terapéutico , Apnea Obstructiva del Sueño/tratamiento farmacológico , Resistencia de las Vías Respiratorias/efectos de los fármacos , Anfetaminas/farmacología , Análisis de Varianza , Animales , Presión Sanguínea/efectos de los fármacos , Desnervación , Diástole , Evaluación Preclínica de Medicamentos , Nervio Hipogloso/fisiología , Neuronas Motoras/efectos de los fármacos , Músculos Faríngeos/efectos de los fármacos , Músculos Faríngeos/inervación , Músculos Faríngeos/fisiopatología , Ratas , Ratas Zucker , Receptor de Serotonina 5-HT2A/fisiología , Receptor de Serotonina 5-HT2C/fisiología , Mecánica Respiratoria/efectos de los fármacos , Agonistas del Receptor de Serotonina 5-HT2 , Agonistas de Receptores de Serotonina/farmacología , Apnea Obstructiva del Sueño/etiología , Apnea Obstructiva del Sueño/fisiopatología , Sístole , Delgadez/complicacionesRESUMEN
Several studies indicate a role for the serotonin 2 subfamily (5-HT(2A), 5-HT(2B), 5-HT(2C)) in mediation of fear and anxiety responses. The current study began to examine the effects of stimulating 5-HT(2C) receptors within the basolateral (BLA) or central nucleus of the amygdala (CeA) on acute fear-like responses in rats. Bilateral intra-BLA infusions of mCPP (3-3000 pmol), a mixed 5-HT(2) agonist, produced ultrasonic vocalization and reduced exploratory behavior while increasing the latency to investigate a novel object. These responses were attenuated by SB-242084, a 5-HT(2C)-specific antagonist. Furthermore, a selective 5-HT(2C) agonist, IL-639, produced a similar repertoire of behavioral effects with the exception of effects on time spent in the center of an open-field arena. Finally, infusions of mCPP into the CeA produced no anxiogenic behaviors suggesting that 5-HT(2C) receptors primarily within the BLA are responsible for many of the acute fear-like responses reported here. To characterize further the neural circuits associated with 5-HT(2C)-mediated fear responses, we assessed c-fos mRNA expression after intra-BLA infusions of mCPP, IL-639 or their vehicles. Whereas the overall regional pattern of c-fos mRNA induction for the two compounds was distinct, c-fos activation was confined primarily to limbic nuclei with the medial prefrontal cortex as a common regional target of each drug. These results suggest that activation of 5-HT(2C) receptors within the BLA influences the activity of limbic circuits involved in the expression of acute innate fear responses.